Updated efficacy and safety results from phase III GLOW study evaluating zolbetuximab plus CAPOX as first-line (1L) treatment for patients with claudin-18 isoform 2-positive (CLDN18.2+), HER2— , locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma Meeting Abstract
| Authors: | Lordick, F.; Shah, M. A.; Shitara, K.; Ajani, J. A.; Bang, Y. J.; Enzinger, P. C.; Ilson, D. H.; van Cutsem, E.; Gallego Plazas, J.; Huang, J.; Shen, L.; Oh, S. C.; Sunpaweravong, P.; Soo, H. H. F.; Türk, H. M.; Park, J. W.; Moran, D.; Bhattacharya, P.; Cao, Y. J.; Xu, R. H. |
| Abstract Title: | Updated efficacy and safety results from phase III GLOW study evaluating zolbetuximab plus CAPOX as first-line (1L) treatment for patients with claudin-18 isoform 2-positive (CLDN18.2+), HER2— , locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma |
| Meeting Title: | ESMO Asia Congress 2023 |
| Journal Title: | Annals of Oncology |
| Volume: | 34 |
| Issue: | Suppl. 4 |
| Meeting Dates: | 2023 Dec 1-3 |
| Meeting Location: | Singapore |
| ISSN: | 0923-7534 |
| Publisher: | Oxford University Press |
| Date Published: | 2023-11-01 |
| Start Page: | S1524 |
| Language: | English |
| ACCESSION: | WOS:001122475400138 |
| DOI: | 10.1016/j.annonc.2023.10.270 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 134MO -- Source: Wos |
